Study of golidocitinib plus immunotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of golidocitinib (a targeted pill) and an immunotherapy drug (anti-PD-1) for people with non-small cell lung cancer that has come back or spread after prior treatment. It aims to see if this new combination can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) that is stage IIIB/IIIC or stage IV and cannot be removed with surgery.
- You have already been treated with an immunotherapy (PD-1 inhibitor) as your first treatment, either with or without chemotherapy, and your cancer stayed stable or shrank for at least 6 weeks.
- You are 18 or older and are in fairly good health (able to do most daily activities without help).
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver and kidney function are within certain limits (the study team will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of golidocitinib (a targeted pill) and a PD-1 inhibitor (a type of immunotherapy) as a maintenance treatment after initial chemotherapy. It may help keep your lung cancer from growing longer.
This trial tests a combination of two drugs—golidocitinib (a targeted pill) and sintilimab (an immunotherapy)—for people with advanced non-small cell lung cancer that has a high PD-L1 protein level. It may offer a new option if you haven't had immunotherapy before.
This trial tests a drug called golidocitinib for people with advanced lung cancer who developed serious, hard-to-treat blood-related side effects (like low white blood cells, low platelets, or anemia) from immunotherapy. The goal is to see if golidocitinib can help reverse these side effects without stopping cancer treatment.
This trial tests a new oral medication called golidocitinib for people who have just been diagnosed with a specific type of T-cell lymphoma and have not had any prior treatment. The goal is to see if this JAK1 inhibitor can help control the disease.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.